Genotoxic factors associated with the development of receptor-negative breast cancer: Potential role of the phenomenon of switching of estrogen effects

Experimental Oncology

Volumn 28, Issue 1, 2006, Pages 64-69

  Berstein, L M ^a   Tsyrlina, E V ^a   Poroshina, T E ^a   Levina, V V ^b   Vasilyev, D A ^a   Kovalenko, I G ^a   Semiglazov, V F ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b INSTITUTE OF CYTOLOGY   (Russian Federation)

Author keywords

8 Hydroxy 2 deoxyguanosine (8 OH DG); Breast cancer; Diabetes; Genotoxicity; Smoking; Steroid receptors

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BIOLOGICAL MARKER; DEOXYGUANOSINE DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR; FLAVONE DERIVATIVE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA DAMAGE; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DEOXYGUANOSINE; DIABETES COMPLICATIONS; DNA DAMAGE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SMOKING;

EID: 33646073085     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Berstein LM. Hormonal carcinogenesis. Saint-Petersburg: Nauka, 2000; 199.
2. Berstein LM. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett 2005; 224: 203-12.
3. Berstein LM, Kovalevskij A, Larionov A, Maximov S, Volkov ON. Aromatase activity in receptor-negative breast and endometrial cancer. Exp Oncol 2003; 25: 228-30.
4. Berstein L, Tsyrlina E, Poroshina T, Bychkova N, Kalinina N, Gamajunova V, Vasilyev D, Kovalenko I. Switching (over-targeting) of estrogen effects and its potential role in hormonal carcinogenesis. Neoplasma 2002; 49: 21-5.
5. Bianco NR, Chaplin LJ, Montano MM. Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damage. Biochem J 2005; 385: 279-87.
6. Bianco NR, Perry G, Smith MA, Montano MM. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage. Mol Endocrinol 2003; 17: 1344-55.
7. Ceriello A, Mercuri F, Quagliaro L, Owens D, Tajima N, Tuomilehto J. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001; 44: 834-8.
8. Clarke RB. Steroid receptors and proliferation in the human breast. Steroids 2003; 68: 789-94.
9. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif 2003; 36: 59-72.
10. Fan S, Ma YX, Wang C. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 2001; 20: 77-87.
11. Fisher B, Osborne CK, Margolese R, Bloomer WD. Neoplasms of the breast. In: Cancer Medicine, 4 edition. Holland JF et al., eds. Baltimore-Philadelphia: Williams & Wilkins, 2001; 2349-432.
12. Fuqua SAW. Estrogen and progesterone receptors and breast cancer. In: Diseases of breast. Harris JR et al., eds. Philadelphia: Lippincott-Raven, 1996; 185-200.
13. Habel LA, Stanford JL. Hormone receptors and breast cancer. Epidemiol Revs 1993; 15: 209-19.
14. Karbownik M, Reiter RJ, Burkhardt S, Smith OP, Wester G. Melatonin attenuates estradiol-induced oxidative damage to DNA: relevance for cancer progression. Exp Biol Med 2001; 226: 707-12.
15. Kushlinsky NE, Gershtein ES. Contemporary approaches to molecular-biochemical evaluation of biological behaviour of breast tumors. Vestn Russ Acad Med Sci 2001; 9: 65-70.
16. Leu YW, Yan PS, Fan M, Wang X, Yu E. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004; 64: 8184-92.
17. Manier J, Andersson I, Berglund G, Johansson R, Lenner P. Survival of women with breast cancer in relation to smoking. Eur J Surg 2000; 166: 852-8.
18. Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, Manson JE. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 2003; 26: 1752-8.
19. Mueck AO, Seeger H, Wallwiener D. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause 2003; 10: 332-6.
20. Musarrat J, Arezina-Wilson J, Wani AA. Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis. Eur J Cancer 1996; 32A: 1209-14.
21. Quong J, Eppenberger-Castori S, Moore D, III, Scott GK, Birrer MJ, Benz CC. Age-dependent changes in breast cancer hormone receptors and oxidant stress markers. Breast Cancer Res Treatment 2002; 76: 221-36.
22. Saez S, Martin PM, Chouvet CD. Oestradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels. Cancer Res 1978; 38: 3468-73.
23. Safe SH, Pallaroni L, Yoon K, Gaido K, Ross S, McDonnell D. Problems for risk assessment of endocrine-active estrogenic compounds. Environ Health Perspect 2002; 110: 925-9.
24. Santen RJ. Risk of breast cancer with progestins: critical assessment of current data. Steroids 2003; 68: 953-64.
25. Sorlie T, Perou C, Tibshirani R, Geisler S, Lonning PE, Borresen-Dale A-L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
26. Surkov KG, Tsyrlina EV, Konstantinova MM, Berstein LM. Interferon inductor neovir modifies expression of steroid receptors and restores hormonal sensitivity in breast cancer. Vopr Oncol 1996; 42: 28-32.
27. Tansavatdi K, McClain B, Herrington DM. The effects of smoking on estradiol metabolism. Minerva Ginecol 2004; 56: 105-14.
28. Tarone RE, Chu KC. The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation. Cancer Causes Control 2002; 13: 7-14.
29. Tsai MJ, Clark J, Scrader WT, O'Malley BW. Mechanisms of action of hormones that act as transcription-regulatory factors. In: Williams textbook of endocrinology. Wilson JD et al., eds. 1998; 55-87.
30. Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao YT, Wu AH, Zaridze D, Peto R, Doll R. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 2004; 96: 99-106.
31. Yancik R, Wesley MN, Ries LA, Calle EE. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001; 285: 885-92.
32. Yasui Y, Potter JD. The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 1999; 10: 431-7.